Form 4: Opus Genetics CEO Reports Automatic Share Sale

CEO George Magrath sold 9,511 shares of Opus Genetics to satisfy tax obligations related to restricted stock unit vesting.

Summary

• George Magrath, CEO of Opus Genetics, Inc., sold 9,511 shares of common stock on April 23, 2026.
• The shares were sold at a price of $5.22 per share.
• Following the transaction, the CEO retains beneficial ownership of 1,741,344 shares.
• The sale was executed automatically to cover tax withholding obligations resulting from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was mandatory for tax purposes and does not reflect a change in management sentiment.

Positives

• The transaction was non-discretionary, indicating it was not a signal of management's view on the company's future performance.

Negatives

• Reduction in the CEO's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction related to tax compliance.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The filing notes that the transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for executives in the biotechnology sector to manage tax liabilities associated with equity compensation vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and relatively small compared to total holdings.

Next Steps

• None specified.

Key Dates

Keywords

Opus Genetics, IRD, Insider Trading, Form 4, Executive Compensation, Tax Withholding